


ELUVIA™ Drug-Eluting Stent: Outlasts Zilver PTX, Outperforms Expectations

The standard of care in SFA stenting

See why
more physicians
choose Eluvia DES,
the #1 SFA stent
in the U.S.²⁸

**Eluvia DES's polymer elutes paclitaxel when it's most critical.
Zilver PTX's paclitaxel stops short**




Eluvia DES releases Paclitaxel for ~365 days
matching the SFA restenotic cascade²

Zilver PTX, a drug-coated stent without a polymer, releases all paclitaxel within 72 hours and paclitaxel is gone by 56 days³

**Eluvia DES delivers unrivalled clinical outcomes at 1 and 2 years,
the time that matters the most**

Eluvia DES has demonstrated
superiority over Zilver PTX at 1 year⁴


IMPERIAL RCT
1-YEAR K-M PRIMARY PATENCY⁵



Logrank p=0.0094
N=465 at 65 sites worldwide


Eluvia DES revascularization rates
statistically lower than Zilver PTX at 2 years⁶

IMPERIAL RCT
2-YEAR TLR RATES




In an SFA stent meta-analysis of 142 publications with more than 52,000 patients,
Eluvia DES demonstrated **higher primary patency** and **lower TLR rates** than
Zilver PTX, Viabahn and BMS at 1 and 2 years⁷

PRIMARY PATENCY




TARGET LESION REVASCULARIZATION



No matter the trial, lesion length or complexity, Eluvia DES outcomes are consistent.

1 YEAR PRIMARY PATENCY AND AVERAGE LESION LENGTH⁸⁻²⁷ ELUVIA DES VS. ZILVER PTX



1 YEAR PRIMARY PATENCY⁸⁻¹⁹


96.4%	MAJESTIC
85.4%	EMINENT RCT
92.1%	IMPERIAL RCT
92.2%	REGAL
94.0%	AUCKLAND
91.0%	IMPERIAL LL
88.0%	CAPSICUM
91.0%	DESAFINADO
90.0%	MÜNSTER
85.8%	ULTIMATE
88.2%	SPORTS RCT

1 YEAR PRIMARY PATENCY²⁰⁻²⁷

83.1%	ZILVER PTX RCT	79.9%	REAL-PTX ZPTX
91.0%	BATTLE Zilver PTX	63.0%	ZEPHYR Zilver PTX
81.8%	IMPERIAL ZPTX	77.6%	ZILVER PTX Single-Arm TASC C/D
86.2%	Zilver PTX Single-Arm Clinical Study	52.5%	STELLA-PTX Registry

It's clear why Eluvia DES is the #1 SFA stent in the U.S.²⁸

When a stent is needed, don't just settle for Zilver PTX, choose Eluvia DES



1. Iida, O. et al. Catheterization and Cardiovascular Interventions. 2011; 78:611-617. 2. Müller-Hülsbeck S. Expert Opin Drug Deliv. 2016;13(11):1639-1644. 3. Dake MD, et al. J Vasc Interv Radiol. 2011;22(5):603-610; 4. Superiority determined in a post hoc analysis that was specified prior to unblinding. 12-Month Primary Patency rate of 86.8% in the Eluvia arm vs. 77.5% in the Zilver PTX arm (p-value=0.0144). Gray WA, Lancet, 2018 Sep 24. pii:S01406736(18)32262-1. 5. Gray WA, LINC 2020 6. Müller-Hülsbeck S, et al. Two-Year Efficacy and Safety Results from the IMPERIAL Randomized Study of the Eluvia Polymer-Coated Drug-Eluting Stent and the Zilver PTX Polymer-free Drug-Coated Stent. Cardiovasc Interv Radiol. 2021;44(3):368-375. doi:10.1007/s00270-020-02693-1 7. Holden, A. Performance of Stenting in Femoropopliteal Disease: Systematic Literature Review and Meta-analysis of Proportions. Presented at Charing Cross 2025.

Eluvia Trials:

8. MAJESTIC Müller-Hülsbeck S, et al. Cardiovasc Interv Radiol. 2017;40(12):1832-1838. 9. EMINENT Gouëffri c Y, et al. Circulation. 2022;146(21):1564-1576. 10. IMPERIAL Gray WA, LINC 2020. 11. REGAL Lansink W, LINC 2023. 12. AUCKLAND Holden A, LINC 2020. 13. IMPERIAL LL Golzar J, et al. J Endovasc Ther. 2020;27(2):296-303. 14. CAPSICUM Iida O, et al. JACC Cardiovasc Interv. 2022;15(6):630-638. 15. DESAFINADO Kum S, et al. Vasc Med. 2021;26(3):267-272. 16. DESAFINADO 91% corresponds with the DESAFINADO "complete lesion coverage" subgroup. 17. MUNSTER Stavroulakis K, et al. JACC Cardiovasc Interv. 2021;14(6):692-701. 18. ULTIMATE Ichihashi S, et al. Eur J Vasc Endovasc Surg. 2022;64(4):359-366. 19. SPORTS Tepe, G. Charing Cross 2025

Zilver PTX Trials:

20. ZILVER PTX RCT Dake MD, et al. Circulation. 2016 Apr 12;133(15):1472-83. 21. BATTLE Gouëffri Y et al. JACC Cardiovasc Interv. 2020 Feb 24;13(4):447-457. 22. IMPERIAL Gray WA, LINC, 2020. 23. Zilver PTX Single Arm Dake MD, et al. J Endovasc Ther 2011;18:613-23. 24. REAL PTX Bausback Y, et al. J Am Coll Cardiol. 2019 Feb19;73(6):667-679. 25. ZEPHYR Iida O, et al. JACC Cardiovasc Interv. 2015 Jul;8(8):1105-1112. 26. ZILVER PTX Bosiers M, J Cardiovasc Surg (Torino). 2013 Feb;54(1):115-22. 27. STELLA PTX Davaine JM, et al. Eur J Vasc Endovasc Surg. 2015 Nov;50(5):631-7

28. Data on file at Boston Scientific. DRG US hospital market data, June 2025

Boston Scientific
Advancing science for life™

Peripheral Interventions
300 Boston Scientific Way
Marlborough, MA 01752-1234
bostonscientific.com

To order product or for more information contact customer service at 1.888.272.1001

© 2025 Boston Scientific Corporation or its affiliates. All rights reserved.

PI-1812406-AD



ELUVIA™ Drug-Eluting Stent
Indications, Safety, and Warnings